articles
pensatoryandneutralizingactions,4antitargetandcounter-targetactivities,5andon-targetandoff-targettoxicities.6Multitargetagentsanddrugcombinationshavebeenincreas-inglyexplored1,7forenhancingtherapeuticef caciesandimprovingsafetyandresistancepro lesbyselectivelymodulatingtheelementsofthesecountertargetandtoxicityactivities.8Inparticular,multitargetkinaseinhibitorsareamongthemostsuccessfulclinicalanticancerdrugs(e.g.,sunitinibagainstPDGFRandVEGFR,dasatinibagainstAblandSrc,sorafenibagainstBrafandVEGFR,andlapatinibagainstEGFRandHER2)andhavebeenactivelypursuedincurrentdrugdiscoveryefforts.9,10Methodsforef cientsearchofmultitargetagentsarehighlydesired.
Virtualscreening(VS)methodshavebeenwidelyexploredforfacilitatingleaddiscoveryagainstindividualtargets.11-13Inparticular,moleculardocking,14pharmacophore,15QSAR,16machinelearning,17andcombinationmethods18havebeenextensivelyusedforVSofsingle-targetkinaseinhibitors,butfewmultitargetVSstudieshavebeen
(3)Muller,R.Crosstalkofoncogenicandprostanoidsignaling
pathways.J.CancerRes.Clin.Oncol.2004,130(8),429–44.(4)Sergina,N.V.;Rausch,M.;Wang,D.;Blair,J.;Hann,B.;Shokat,
K.M.;Moasser,M.M.EscapefromHER-familytyrosinekinaseinhibitortherapybythekinase-inactiveHER3.Nature2007,445(7126),437–41.
(5)Overall,C.M.;Kleifeld,O.Validatingmatrixmetalloproteinases
asdrugtargetsandanti-targetsforcancertherapy.Nat.ReV.Cancer2006,6,227–39.
(6)Force,T.;Krause,D.S.;VanEtten,R.A.Molecularmechanisms
ofcardiotoxicityoftyrosinekinaseinhibition.Nat.ReV.Cancer2007,7(5),332–44.
(7)Keith,C.T.;Borisy,A.A.;Stockwell,B.R.Multicomponent
therapeuticsfornetworkedsystems.Nat.ReV.DrugDiscoVery2005,4(1),71–8.
(8)Larder,B.A.;Kemp,S.D.;Harrigan,P.R.Potentialmechanism
forsustainedantiretroviralef cacyofAZT-3TCcombinationtherapy.Science1995,269(5224),696–9.
(9)Krug,M.;Hilgeroth,A.Recentadvancesinthedevelopmentof
multi-kinaseinhibitors.Mini-ReV.Med.Chem.2008,8(13),1312–27.
(10)Gill,A.L.;Verdonk,M.;Boyle,R.G.;Taylor,R.Acomparison
ofphysicochemicalpropertypro lesofmarketedoraldrugsandorallybioavailableanti-cancerproteinkinaseinhibitorsinclinicaldevelopment.Curr.Top.Med.Chem.2007,7(14),1408–22.(11)Shoichet,B.K.Virtualscreeningofchemicallibraries.Nature
2004,432(7019),862–5.
(12)Yamane,S.;Ishida,S.;Hanamoto,Y.;Kumagai,K.;Masuda,R.;
Tanaka,K.;Shiobara,N.;Yamane,N.;Mori,T.;Juji,T.;Fukui,N.;Itoh,T.;Ochi,T.;Suzuki,R.Proin ammatoryroleofamphiregulin,anepidermalgrowthfactorfamilymemberwhoseexpressionisaugmentedinrheumatoidarthritispatients.J.In am-mation(London,U.K.)2008,5,5.
(13)Ma,X.H.;Wang,R.;Yang,S.Y.;Li,Z.R.;Xue,Y.;Wei,Y.C.;
Low,B.C.;Chen,Y.Z.Evaluationofvirtualscreeningperformanceofsupportvectormachinestrainedbysparselydistributedactivecompounds.J.Chem.Inf.Model.2008,48(6),1227–37.
(14)Gozalbes,R.;Simon,L.;Froloff,N.;Sartori,E.;Monteils,C.;
Baudelle,R.Developmentandexperimentalvalidationofadockingstrategyforthegenerationofkinase-targetedlibraries.J.Med.Chem.2008,51(11),3124–32.1546
MOLECULARPHARMACEUTICSVOL.7,NO.5
Maetal.
reported.19,20Aninterestingstrategyforidentifyingmulti-targetkinaseinhibitorsistouseexperimentallyobtainedsmall-scalepro lesforpredictinginhibitorsofalargerkinaseset.20Inprinciple,single-targetVStoolsmaybecombinedtocollectivelyidentifymultitargetagents,whichispracticallyusefuliftheindividualVStoolshavesuf cientlyhighyieldsandlowfalse-hitrates.HighyieldscompensateforthereducedcollectiveyieldsofcombinatorialVStools(fortwostatisticallyindependentVStoolsof50%-70%yields,thecollectiveyieldoftheircombinationisroughlytheproductoftheyieldofindividualtools,whichis25%-49%).Lowfalse-hitratesareneededforhighenrichmentfactorsinsearchingmultitargetagentsthataresigni cantlyfewerinnumbersandmoresparselydistributedinthechemicalspacethannon-dual-inhibitors(Table1).
Anextensivelyusedmachinelearningmethod,supportvectormachines(SVM),maybepotentiallyexploredasmultitargetVStoolsbecauseithasshownhighyieldsandlowfalse-hitratesinsearchingsingle-targetagents21some-timesbasedonsparselydistributedactivecompounds.13SVM,trainedbasedonthephysicochemicalpropertiesofactiveandinactivecompounds,identi esactivecompoundsinfastspeedbydifferentiatingphysicochemicalpro lesratherthanstructuralsimilaritytoactivecompoundsperse,andrequiresnoknowledgeoftargetstructureandnocomputationofstructural exibility,activity-relatedfeatures,solvationeffectsandbindingaf nities.MultitargetVSperformanceofcombinatorialSVMs(C-SVM),whichcom-(15)Deng,X.Q.;Wang,H.Y.;Zhao,Y.L.;Xiang,M.L.;Jiang,
P.D.;Cao,Z.X.;Zheng,Y.Z.;Luo,S.D.;Yu,L.T.;Wei,Y.Q.;Yang,S.Y.Pharmacophoremodellingandvirtualscreeningforidenti cationofnewAurora-Akinaseinhibitors.Chem.Biol.DrugDes.2008,71(6),533–9.
(16)Deanda,F.;Stewart,E.L.;Reno,M.J.;Drewry,D.H.Kinase-TargetedLibraryDesignthroughtheApplicationofthePharm-PrintMethodology.J.Chem.Inf.Model.2008,48(12),2395–403.
(17)Briem,H.;Gunther,J.Classifying“kinaseinhibitor-likeness”by
usingmachine-learningmethods.ChemBioChem2005,6(3),558–66.
(18)Gundla,R.;Kazemi,R.;Sanam,R.;Muttineni,R.;Sarma,J.A.;
Dayam,R.;Neamati,N.Discoveryofnovelsmall-moleculeinhibitorsofhumanepidermalgrowthfactorreceptor-2:combinedligandandtarget-basedapproach.J.Med.Chem.2008,51(12),3367–77.
(19)Prado-Prado,F.J.;delaVega,O.M.;Uriarte,E.;Ubeira,F.M.;
Chou,K.C.;Gonzalez-Diaz,H.Uni edQSARapproachtoantimicrobials.4.Multi-targetQSARmodelingandcomparativemulti-distancestudyofthegiantcomponentsofantiviraldrug-drugcomplexnetworks.Bioorg.Med.Chem.2009,17(2),569–75.
(20)Zhang,X.;Fernandez,A.Insilicodrugpro lingofthehuman
kinomebasedonamolecularmarkerforcrossreactivity.Mol.Pharmaceutics2008,5(5),728–38.
(21)Han,L.Y.;Ma,X.H.;Lin,H.H.;Jia,J.;Zhu,F.;Xue,Y.;Li,
Z.R.;Cao,Z.W.;Ji,Z.L.;Chen,Y.Z.Asupportvectormachinesapproachforvirtualscreeningofactivecompoundsofsingleandmultiplemechanismsfromlargelibrariesatanimprovedhit-rateandenrichmentfactor.J.Mol.GraphicsModel.2008,26(8),1276–86.
Synthesis and Characterization of Pyrazoleanthrone Derivatives as Aurora A Kinase Inhibitors_生产/经营管理_经管营销_专业资料。Chem.Res.Chin.Univ.2013.29(6)...
Synthesis and Characterization of Pyrazoleanthrone Derivatives as Aurora A Kinase Inhibitors_生产/经营管理_经管营销_专业资料。Chem.Res.Chin.Univ.2013.29(6)...
热门文档